692 related articles for article (PubMed ID: 17512856)
41. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
Pritchard KI
Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
[No Abstract] [Full Text] [Related]
42. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility.
Franco JG; Oliveira JB; Petersen CG; Mauri AL; Baruffi R; Cavagna M
Med Hypotheses; 2012 Apr; 78(4):442-5. PubMed ID: 22284634
[TBL] [Abstract][Full Text] [Related]
44. Adjuvant endocrine therapy in premenopausal women with breast cancer.
González Martín A; de la Cruz S; Márquez R
Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
[No Abstract] [Full Text] [Related]
45. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet Oncol; 2022 Mar; 23(3):382-392. PubMed ID: 35123662
[TBL] [Abstract][Full Text] [Related]
46. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
Rydén L; Jönsson PE; Chebil G; Dufmats M; Fernö M; Jirström K; Källström AC; Landberg G; Stål O; Thorstenson S; Nordenskjöld B; ;
Eur J Cancer; 2005 Jan; 41(2):256-64. PubMed ID: 15661551
[TBL] [Abstract][Full Text] [Related]
47. Can endocrine treatment for hormone-positive premenopausal women with early breast cancer replace adjuvant chemotherapy?
Malayeri R
J Clin Oncol; 2003 Jun; 21(12):2444-5; author reply 2446-7. PubMed ID: 12805348
[No Abstract] [Full Text] [Related]
48. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
49. Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women.
Jonat W
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):1-5. PubMed ID: 11900209
[TBL] [Abstract][Full Text] [Related]
50. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
51. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
[TBL] [Abstract][Full Text] [Related]
53. The influence of endocrine treatments for breast cancer on health-related quality of life.
Buijs C; de Vries EG; Mourits MJ; Willemse PH
Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
[TBL] [Abstract][Full Text] [Related]
54. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
[TBL] [Abstract][Full Text] [Related]
55. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.
Cheer SM; Plosker GL; Simpson D; Wagstaff AJ
Drugs; 2005; 65(18):2639-55. PubMed ID: 16392882
[TBL] [Abstract][Full Text] [Related]
56. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives.
Del Mastro L; Levaggi A; Giraudi S; Pronzato P
Cancer Treat Rev; 2011 May; 37(3):208-11. PubMed ID: 20724078
[TBL] [Abstract][Full Text] [Related]
57. Ovarian ablation as treatment for young women with breast cancer.
Davidson NE
J Natl Cancer Inst Monogr; 1994; (16):95-9. PubMed ID: 7528032
[TBL] [Abstract][Full Text] [Related]
58. Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer.
Sendur MA; Aksoy S; Ozdemir NY; Zengin N; Yazici O; Sever AR; Altundag K
J BUON; 2016; 21(1):27-34. PubMed ID: 27061527
[TBL] [Abstract][Full Text] [Related]
59. Adjuvant therapy for premenopausal patients with early breast cancer.
Kurebayashi J
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):51-4. PubMed ID: 18197006
[TBL] [Abstract][Full Text] [Related]
60. Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation.
Jonat W
Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S23-6: discussion S33-5. PubMed ID: 12353820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]